Positron Emission Tomography-Computed Tomography for Rheumatology Indications: Diagnostic Accuracy, Clinical Utility, Cost-Effectiveness, and Evidence-Based Guidelines


( Last Updated : November 6, 2018)
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1275-000

Details


Final Biosimilar Summary Dossier Issued:

Question


  1. What is the diagnostic test accuracy of positron emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis (GCA) or Takayasu’s vasculitis?

  2. What is the clinical utility of positron emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis (GCA) or Takayasu’s vasculitis?

  3. What is the cost-effectiveness of positron emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis or Takayasu’s vasculitis?

  4. What are the evidence-based guidelines associated with the use of positron-emission tomography-computed tomography (PET-CT) in patients with Giant Cell Arteritis (CGA) or Takayasu’s vasculitis?


Key Message

Four non-randomized studies were identified regarding fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) for patients with Giant Cell Arteritis (GCA). No evidence was identified for Takayasu's vasculitis. No economic evaluations or evidence-based guidelines were identified.